News Releases
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
VANCOUVER, Canada, February 6, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Vancouver, Canada, January 29, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Topline data from the chronic cohort is expected in Q2 2025 Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for
NervGen Announces “At-The-Market” Equity Program
Vancouver, Canada, December 20, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completion NVG-300
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
Vancouver, Canada, November 7, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Target enrollment in the chronic cohort close to completion Vancouver, Canada, September 30, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
Vancouver, Canada, September 20, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
Vancouver, Canada, September 16, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, Canada, August 27, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024 Protocol being amended to enhance enrollment and lessen burden on participants in
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Vancouver, Canada, August 6, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of
NervGen Pharma Grants Stock Options
Vancouver, Canada. August 2, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the
NervGen Pharma Appoints Neil Klompas to Board of Directors
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company’s mission to advance NVG-291 after the completion
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, Canada June 25, 2024